Abstract 2991: Mutational screening of BRCA1/2 genes in 667 spontaneous canine tumors

Author(s):  
Benjamin Lewis ◽  
Gerry Post ◽  
Garrett Harvey ◽  
Lindsay Lambert ◽  
Aubrey Miller ◽  
...  
Immunobiology ◽  
2020 ◽  
Vol 225 (2) ◽  
pp. 151892 ◽  
Author(s):  
P. Cruz ◽  
E. Sosoniuk-Roche ◽  
I. Maldonado ◽  
C.G. Torres ◽  
A. Ferreira

2015 ◽  
Vol 62 (7) ◽  
pp. 1195-1201 ◽  
Author(s):  
R. Berrueco ◽  
A. Alonso-Saladrigues ◽  
L. Martorell-Sampol ◽  
A. Català-Temprano ◽  
A. Ruiz-Llobet ◽  
...  

2002 ◽  
Vol 19 (3) ◽  
pp. 287-295 ◽  
Author(s):  
Alessia Colosimo ◽  
Valentina Guida ◽  
Alessandro De Luca ◽  
Maria Pia Cappabianca ◽  
Ida Bianco ◽  
...  
Keyword(s):  

2003 ◽  
Vol 22 (6) ◽  
pp. 496-496
Author(s):  
Velamakanni Saroj Kiran ◽  
Chitra Kannabiran ◽  
Kalyana Chakravarthi ◽  
Geeta K. Vemuganti ◽  
Santosh G. Honavar

2012 ◽  
Vol 16 (12) ◽  
pp. 1395-1400 ◽  
Author(s):  
Mehri Igci ◽  
Ecir Ali Cakmak ◽  
Serdar Oztuzcu ◽  
Ali Bayram ◽  
Ahmet Arslan ◽  
...  

2015 ◽  
Vol 5 (5S) ◽  
pp. 7-14
Author(s):  
Sabina Russo ◽  
Giuseppa Penna ◽  
Arianna D’Angelo ◽  
Alessandro Allegra ◽  
Andrea Alonci ◽  
...  

This article describes the case of a 44 year old man, at high-risk according to the Sokal Index, after CML Ph+ diagnosis, started imatinib at the standard dose (400 mg/day). Initially he reached optimal response, but at month 12, because of a loss of cytogenetic response, he was documented as a treatment failure. The mutational screening revealed no mutations and the blood level testing (BLT) showed values of ​​lower limits, therefore he increased imatinib to 800 mg/day. This therapeutic choice did not result in the achievement of an optimal response and the imatinib compliance was deteriorated. So, after nearly 12 months of treatment with high dose imatinib, we considered the treatment as a failure, and he switched to nilotinib, at the dose of 800 mg/day. After only 3 months of treatment, he reached complete cytogenetic response (CCyR) and major molecular response (MMolR), which the patient continues to maintain, as documented by the recent evaluation at month 30.


2009 ◽  
Vol 15 (6) ◽  
pp. 468-470 ◽  
Author(s):  
Elena Sánchez-Ferrero ◽  
Eliecer Coto ◽  
Marta Blázquez ◽  
René Ribacoba ◽  
Luis M. Guisasola ◽  
...  

2007 ◽  
Vol 9 (1) ◽  
pp. 37-43 ◽  
Author(s):  
Maria Medin ◽  
Manuel Hermida-Prieto ◽  
Lorenzo Monserrat ◽  
Rafael Laredo ◽  
Jose Carlos Rodriguez-Rey ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document